School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

AVITA Medical Inc RCEL

Healthcare · Biotechnology

$13.21last close 2026-10-09 · market cap $413.49M · delayed data

Trailing returns

1M+30.02%
3M+199.55%
6M+190.97%
1Y+138.88%
5Y-22.84%

Basis: Adjusted daily closes.

What it does

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.

Open RCEL in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies